Infections in outpatients with systemic lupus erythematosus: A prospective study

Lupus

Volumn 10, Issue 7, 2001, Pages 505-510

  Zonana Nacach, A ^a   Camargo Coronel, A ^a   Yanez P ^a   Sanchez L ^a   Jimenez Balderas, F J ^a   Fraga, A ^a  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

Infections; Outpatients; Risk factors; Systemic lupus erythematosus

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; DISEASE ACTIVITY; FEMALE; HOSPITALIZATION; HUMAN; INFECTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; URINARY TRACT INFECTION; VAGINITIS;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFECTION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OUTPATIENTS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0034927138     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120301678416088     Document Type: Article

References (46)

1. Systemic lupus erythematosus: Survival patterns
2. Long-term survival in systemic lupus erythematosus: Patient characteristics associated with poorer outcomes
3. Incidence and risk factors for hospitalization in systemic lupus erythematosus
4. Prognosis of systemic lupus erythematosus and factors that affect it
5. Pathology of disseminated lupus erythematosus
6. A multicenter study of outcome in systemic lupus erythematosus: II. Causes of death
7. Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort
8. Relation between the level of IgG subclasses and infections in patients with systemic lupus erythematosus
9. Complement deficiency states and infection: Epidemiology, pathogenesis and consequences of Nisserial and other infections in an immune deficiency
10. Infection in systemic lupus erythematosus: Associations with a serum inhibitor of complement-derived chemotactic activity
11. Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus
12. Defective phagocytosis, decreased tumor necrosis factor-alpha production, and lymphocyte hyporesponsiveness predispose patients with systemic lupus erythematosus to infections
13. Outcome in systemic lupus erythematosus: A prospective study of patients from a defined population
14. Systemic lupus erythematosus: A review of 110 cases with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis
15. Morbidity associated with childhood systemic lupus erythematosus
16. Incidence of infection in systemic lupus erythematosus
17. Infection and immuno-suppression: A study of the infective complications of 75 patients with immunologically-mediated diseases
18. Infection and disease activity in systemic lupus erythematosus: A review of hospitalized patients
19. Risk factors for serious infection during treatment with ciclophosphamide and high-dose corticosteroids for systemic lupus erythematosus
20. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus
21. Systemic lupus erythematosus and infection: A controlled study including an epidemiological group
22. Infection in systemic lupus erythematosus (SLE): A controlled and prospective study
23. Infection and systemic lupus erythematosus: Analysis of a series of 145 patients
24. Fatal infections in systemic lupus erythematosus: The role of opportunistic organisms
25. Infections in systemic lupus erythematosus
26. The 1982 revised criteria for the classification of SLE
27. The role of opportunistic bacteria in human disease
28. Derivation of SLEDAI: A disease activity index for lupus patients
29. The bimodal mortality patterns of systemic lupus erythematosus
30. The course of systemic lupus erythematosus
31. Systemic lupus erythematosus in the first two decades of life
32. Infection in systemic lupus erythematosus
33. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus
34. Infection and host defenses in systemic lupus erythematosus
35. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: A prospective longitudinal study
36. Acute reversible hipoxemia in systemic lupus erythematosus
37. Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs
38. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone alone
39. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus
40. Herpes zoster infections in systemic lupus erythematosus: Risk factors and outcome
41. Diferential diagnosis of fever in systemic lupus erythematosus using discriminant analysis
42. Exacerbation of systemic lupus erythematosus related to cytomegalovirus infection
43. Exacerbation of systemic lupus erythematosus during human parvovirus B19 infection
44. Immunisation of patients with rheumatoid arthritis and systemic lupus erythemtosus
45. Chronic modulation of the auto-immune response following parvovirus B19 infection
46. Systemic lupus erythematosus associated with acute Epstein-Bart virus infection